Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Steven R. Feldman, MD, PhD, discloses that he has served as a consultant for AbbVie, Accordant, Almirall, Alvotech, Arcutis, Arena, Argenx, Biocon, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Forte, Helsinn, Incyte, Janssen, Leo, Lilly, Micreos, Mylan, Novartis, Ono, Ortho Dermatology, Pfizer, Samsung, Sanofi, Sun, UCB, Verrica, Voluntis, and vTv; that he has served on a speaker’s bureau for AbbVie, Alvotech, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, Leo, Lilly, Ortho Dermatology, Regeneron, Sanofi, Sun; that he has received grants/research support from AbbVie, Almirall, Bristol Myers Squibb, Galderma, Incyte, Janssen, Leo, Lilly, Novartis, Ortho Dermatology, Perfect Corp, Pfizer, Target-Derm, and UCB; and that he is a stock/shareholder with Causa Research and Sensal Health.

Sara Richardson has no relevant financial relationships to disclose. 

i3 Health has mitigated all relevant financial relationships.